Efforts to supply the first CBD product to Brazil’s public healthcare system will have to wait a while longer – and there is some dispute between the institute preparing to produce it and the sponsors of a Congress bill ...
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.
